Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of an Alfa-lipoic, Methylsulfonylmethane and Bromelain Dietary Supplement (Opera®) for Aromatase Inhibitor-related Arthralgia Management (AIA)

NCT04161833 is registered in ClinicalTrials.gov with Azienda Ospedaliero-Universitaria Careggi as lead sponsor.

NCT NCT04161833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04161833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of an Alfa-lipoic, Methylsulfonylmethane and Bromelain Dietary Supplement (Opera®) for Aromatase Inhibitor-related Arthralgia Management (AIA)
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Phase
Not applicable
Overall status
Completed
Start date
November 1, 2018
Completion date
November 1, 2019
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthralgia, breast cancer, hormone receptor positive tumor